Home
Science & Technology
Publications

Publications:
Our Research

Filter

Filter

Research Area
Technology
Resource type
Category
216 results found
Jun 7, 2023
Publication
Novavax led
Expert Review of Vaccines
COVID-19, Matrix-M® adjuvant
Pivoting to protein: the immunogenicity and safety of protein-based NVX-CoV2373 as a heterologous booster for inactivated and viral vector COVID-19 vaccines
Marchese AM, Kalkeri R, Vadivale M, et al.
View
Jun 5, 2023
Publication
Novavax led
Expert Review of Vaccine
COVID-19, Matrix-M® adjuvant
Safety, efficacy, and immunogenicity of the NVXCoV2373 vaccine
Underwood E, Dunkle LM, Madhi SA, et al.
View
May 21, 2023
Publication
Novavax led
The Journal of Infectious Diseases
COVID-19, Matrix-M® adjuvant
Strong CD4+ T-Cell Responses to Ancestral and Variant Spike Proteins Are Established by NVX-CoV2373 SARS-CoV-2 Primary Vaccination
Louis Fries, Neil Formica, Raburn M Mallory, et al.
View
May 16, 2023
Publication
Collaborative
Science Immunology
COVID-19, Matrix-M® adjuvant
Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in non-human primates
Routhu NK, Stampfer SD, Lai L, et al
View
Apr 28, 2023
Publication
Novavax led
Human Vaccines & Immunotherapeutics
COVID-19, Matrix-M® adjuvant
The Matrix-M™ adjuvant: A critical component of vaccines for the 21st century
Linda Stertman, Anna-Karin E. Palm, Behdad Zarnegar, et al.
View
Apr 26, 2023
Publication
Novavax led
JAMA Network Open
COVID-19, Matrix-M® adjuvant
Safety, immunogenicity, and efficacy of the NVX-CoV2373 Covid-19 vaccine in adolescents a randomized clinical trial
Germán Áñez, Lisa M. Dunkle, Cynthia L. Gay, et al.
View
Mar 20, 2023
Publication
Novavax led
Pre-print
COVID-19, Matrix-M® adjuvant
Immunogenicity and safety of NVX-CoV2373 as a Homologous or Heterologous booster: A phase 3 randomized clinical trial in adults
Fritz Raisera, Matthew Davisb, Jeffrey Adelglassc, et al.
View
Mar 19, 2023
Publication
Novavax led
Pre-print
COVID-19, Matrix-M® adjuvant
NVX-CoV2373 vaccine efficacy against hospitalization: A post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trial
Anthony M. Marchese, Xiang Zhou, John Kinol, et al.
View
Feb 28, 2023
Publication
Collaborative
Nature Communications
COVID-19, Matrix-M® adjuvant
Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variants
James Logue, Robert M. Johnson, Nita Patel, et al.
View
Feb 1, 2023
Publication
Novavax led
microorganisms
COVID-19, Matrix-M® adjuvant
Severe Acute Respiratory Syndrome Coronavirus 2 Receptor (Human Angiotensin-Converting Enzyme 2) Binding Inhibition Assay: A Rapid, High-Throughput Assay Useful for Vaccine Immunogenicity Evaluation
Plested JS, Zhu M, Cloney-Clark S, et al
View